| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | C HEALTH GP (08225): THIRD AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION | - | HKEx | ||
| Fr | C HEALTH GP (08225): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 17 JULY 2026 | - | HKEx | ||
| 25.06. | C HEALTH GP (08225): (1) PROPOSED GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, (2) RE-ELECTION OF RETIRING DIRECTORS, (3) PROPOSED AMENDMENT TO THE ... | - | HKEx | ||
| 25.06. | C HEALTH GP (08225): PROXY FORM FOR ANNUAL GENERAL MEETING | 4 | HKEx | ||
| 25.06. | C HEALTH GP (08225): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| CHINA HEALTH GROUP INC Aktie jetzt für 0€ handeln | |||||
| 25.06. | C HEALTH GP (08225): PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION | 5 | HKEx | ||
| 25.06. | C HEALTH GP (08225): PROPOSED ADOPTION OF NEW SHARE OPTION SCHEME | 2 | HKEx | ||
| 18.06. | C HEALTH GP (08225): INSIDE INFORMATION - DELAY IN CONVENING ANNUAL GENERAL MEETING AND EXPECTED TIMELINE | - | HKEx | ||
| 04.06. | C HEALTH GP (08225): SUPPLEMENTAL ANNOUNCEMENT DISCLOSURES RELATING TO SHARE OPTION SCHEME AND CONTINUING CONNECTED TRANSACTION | - | HKEx | ||
| 03.06. | C HEALTH GP (08225): VOLUNTARY ANNOUNCEMENT REGARDING PROGRESS IN THE RECOVERY OF TRADE RECEIVABLE BY CHINA HEALTH GROUP INC | - | HKEx | ||
| 29.04. | C HEALTH GP (08225): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | - | HKEx | ||
| 29.04. | C HEALTH GP (08225): ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 02.04. | C HEALTH GP (08225): VOLUNTARY ANNOUNCEMENT - SUPPLEMENTARY INFORMATION REGARDING THE 2025 ANNUAL RESULTS AND FUTURE DEVELOPMENT STRATEGY | - | HKEx | ||
| 30.03. | C HEALTH GP (08225): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 25.03. | C HEALTH GP (08225): ANNOUNCEMENT REGARDING THE OUTCOME OF ARBITRATION ON A HISTORICAL CONTRACT DISPUTE AND ITS IMPACT ON FINANCIAL REPORTS | 1 | HKEx | ||
| 23.03. | C HEALTH GP (08225): POSTPONEMENT OF BOARD MEETING | - | HKEx | ||
| 13.03. | C HEALTH GP (08225): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 02.03. | C HEALTH GP (08225): VOLUNTARY ANNOUNCEMENT REGARDING PROGRESS IN THE RECOVERY OF TRADE RECEIVABLE BY CHINA HEALTH GROUP INC. | - | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASPIRE BIOPHARMA | 6,600 | +0,30 % | Aspire Biopharma Holdings, Inc.: Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB | High-Octane Partnership: Multi-time X Games medalist Jarryd McNeil joins BUZZ BOMB to fuel brand expansion in action sports.Consumer Connection: The collaboration strengthens BUZZ BOMB's commitment... ► Artikel lesen | |
| ZHENGYE BIOTECHNOLOGY | 6,150 | -23,22 % | Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| MERCK KGAA | 131,70 | -2,59 % | Merck KGaA erhält Zulassungserweiterung für Erbitux in der EU | DJ Merck KGaA erhält Zulassungserweiterung für Erbitux in der EU
DOW JONES--Der Darmstädter Pharmakonzern Merck hat in der Europäischen Union eine Zulassungserweiterung für seinen Blockbuster Erbitux... ► Artikel lesen | |
| BAYER | 47,630 | +0,34 % | Bayer und Novo Nordisk feiern Comeback! BioNxt Solutions Aktie als Nächstes? | Mit seiner GLP-1-Therapie in Tablettenform hat Novo Nordisk an der Börse wieder in die Erfolgsspur zurückgefunden. Seit April ist die Aktie des dänischen Pharmakonzerns um fast 50 % auf rund 43 EUR... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 41,190 | +0,29 % | Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last? | ||
| NOVO NORDISK | 43,350 | -0,26 % | Novo nordisk vor kritischer Marke: Steht die Aktie vor einem Kursdesaster? - Was erfahrene Trader jetzt tun | ||
| KARDIGAN | 21,400 | 0,00 % | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,580 | 0,00 % | Cathie Wood Effekt beflügelt Biotech: Startet jetzt die Mega-Rallye bei dieser klinischen Wachstumsperle? | ||
| GSK | 22,160 | -1,55 % | Johnson & Johnson, GSK und Co.: Warum der Wettlauf um Zelltherapie-Plattformen gerade erst beginnt | ||
| PFIZER | 21,730 | +0,23 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 74,22 | -0,52 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,950 | +0,13 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| NOVARTIS | 136,98 | +4,37 % | Neuer Meilenstein: FDA-Entscheidung sorgt für Hoffnung: Novartis gelingt Durchbruch | © Foto: Spencer Jones - picture alliance / Glasshouse ImagesDie FDA hat Fabhalta von Novartis vollständig zugelassen. Das Medikament verlangsamt den Verlust der Nierenfunktion bei einer schweren Autoimmunerkrankung.Novartis... ► Artikel lesen | |
| PERRIGO | 9,176 | -1,14 % | Perrigo Company plc: Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations | Mitigating category headwinds with market share gains through implementation of Three-S plan.
Specialty Care segment achieved net sales and segment operating... ► Artikel lesen | |
| LB PHARMACEUTICALS | 30,840 | -0,19 % | BMO initiates LB Pharmaceuticals stock at Outperform on drug data |